| Literature DB >> 11988110 |
Guy J Leclerc1, Gilles M Leclerc, Julio C Barredo.
Abstract
BACKGROUND: We describe an alternative method to determine mRNA half-life (t1/2) based on the Real-Time RT-PCR procedure. This approach was evaluated by using the beta-actin gene as a reference molecule for measuring of mRNA stability.Entities:
Year: 2002 PMID: 11988110 PMCID: PMC116431 DOI: 10.1186/1475-2867-2-1
Source DB: PubMed Journal: Cancer Cell Int ISSN: 1475-2867 Impact factor: 5.722
Figure 2Real-Time RT-PCR quantification of β-actin mRNA. Standard curve showing amplification efficiencies of ten-fold serial dilutions of the pBactin-231 template. Real-Time PCR amplifications were performed using β-actin specific primers BA67 and BA68. The calculated Ct values were plotted versus the log of the initial amount of pBactin-231 molecules (104 to 109) to generate the standard curve. Squares and circles represent β-actin standards and mRNA samples, respectively.
Figure 1Real-Time RT-PCR amplification plot of β-actin mRNA. Representative RT-PCR plot resulting from the amplification of β-actin cDNA templates (1/20 volume) synthesized from 1 μg of total RNA (see Materials and Methods for details). For each time point, the cDNA was generated and quantified from three independent experiments and run in triplicates. The calculated cycle threshold (Ct = 99) provides an arbitrary cut off point at which a Ct value is assigned for each sample.
Figure 3Half-life of β-actin mRNA in Nalm-6 and CCRF-CEM cells. The CCRF-CEM cells were treated with 5 μM (squares) or 1 μM (circles) Act-D for various times to block mRNA synthesis. Similarly, the Nalm6 cells were treated with 1 μM (lozenges) or 0.5 μM (triangles) Act-D. Total RNA, cDNA, and Real-Time PCR amplification were performed as described in the text. The values represent the mean (±) the standard deviation (SD) of the β-actin RNA copy number per μg of total RNA from three independent experiments. Triplicate determinations were averaged at each data-point. The inset shows the calculated half-life for the β-actin mRNA in each cell line for each treatment.